Tag: US CDC
-

This is Why Shares of Pfizer Could Race Higher
Pfizer is pushing to higher highs. After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses. The stock could push even higher on a US CDC vote.…
